Hisamitsu Pharmaceutical co.,inc.

2019.02.05( 48KB): Hisamitsu Pharmaceutical and Kyowa Hakko Kirin sign Commercialization Agreement for HP-3000, a Potential New Transdermal Patch for Parkinson's Disease in Japan
2019.01.11: FY02/2019 Q3 Results Earnings Release Presentation
2018.12.17(108KB): Notification of a New Drug Application for HP-3070 (Transdermal Patch for the Treatment of Schizophrenia) in the U.S.
2018.12.14(110KB): Notification of the results of Phase III clinical study in opioid analgesic naive patients of the transdermal, pain management patch FENTOS®TAPE (development code:HFT-290)
2018.11.28( 94KB): Notification of listing on the NHI drug price standard and marketing of a new dose "0.5 mg" of 'Fentos® Tape (Development code: HFT-290)' ,Transdermal, Pain management patch
2018.11.09( 17KB): Notification of approval for manufacturing and marketing approval of OABLOK®PATCH in Taiwan (Transdermal, Overactive bladder treatment patch)
2018.10.22( 61KB): Notification of the commencement of the Phase II clinical study of HP-5070 in Japan (a transdermal drug for the treatment of primary local hyperhidrosis)
2018.10.10: FY02/2019 Q2 Results Earnings Release Presentation
2018.09.28( 62KB): Notification of application for manufacturing and marketing approval of HP-3000 (Transdermal, Parkinson's disease treatment patch) in Japan
2018.07.06: FY02/2019 Q1 Results Earnings Release Presentation
2018.07.02( 64KB): Notification of approval of supplemental new drug application (NDA) for the addition of a new 0.5mg dose of the transdermal, pain management patch FENTOS® TAPE (development code: HFT-290)
2018.05.18(340KB): Salonpas Named the World's No.1 OTC Topical Analgesic Patch Brand for the Second Consecutive Year
2018.04.26( 98KB): Noven Pharmaceuticals, Inc. press release :Noven Announces Successful Resolution of FDA Warning Letter
2018.04.10: FY02/2018 Q4 Results Earnings Release Presentation
2018.03.28( 67KB): Notice of Revision of Financial Forecast
2018.02.27(195KB): Notification of the results of Phase III clinical study of HP-3000 in Japan (a transdermal drug for the treatment of Parkinson's disease)
2018.02.08(194KB): Announcement of Establishment of New Company
2018.02.06(276KB): Hisamitsu Pharmaceutical, Becomes an Official Partner (External Pain Relief Products) of the Olympic and Paralympic Games Tokyo 2020!
2018.01.31(110KB): Notification of the results of the Phase III clinical study of HP-3070 (transdermal patch for the treatment of schizophrenia) in the US
2018.01.19(115KB): Notification of the approval of a manufacturing and marketing for ALLESAGA® TAPE (Development Code: HP-3060) in Japan, a transdermal system for the treatment of allergic rhinitis.
2018.01.12: FY02/2018 Q3 Results Earnings Release Presentation
2017.11.08(101KB): Noven Pharmaceuticals, Inc. press release :Noven files patent infringement lawsuit against Alvogen
2017.10.10: FY02/2018 Q2 Results Earnings Release Presentation
2017.09.25( 63KB): Notification of the commencement of the Phase II clinical study of Investigational HP-5000 in the USA (an analgesic transdermal drug)
2017.08.31( 62KB): Notification of submission of supplemental new drug application (NDA) for the addition of a new 0.5mg dose of the transdermal, long-action pain relief patch FENTOS® TAPE (development code:HFT-290)
2017.08.08(128KB): Announcement of Establishment of New Company
2017.07.18(175KB): Notification o f the commencement of the Phase III clinical study of HP-3150 in in Japan for "cancer pain" (an algesic transdermal drug containing NSAIDs)
2017.07.07: FY02/2018 Q1 Results Earnings Release Presentation
2017.05.26( 98KB): Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares
2017.05.18(324KB): Salonpas Has Been Acknowledged as World's No.1 OTC Topical Analgesics Patch Brand By Euromonitor International
2017.04.07(497KB): Announcement regarding Establishment of "the 6th Medium-term Management Policy" (Presentation Material)
2017.04.07( 84KB): Announcement regarding Establishment of "the 6th Medium-term Management Policy"
2017.04.07( 55KB): Announcement of Dividend of Surplus in the Fiscal Year Ended February 2017 (115th Fiscal Year)
2017.04.07: FY02/2017 Q4 Results Earnings Release Presentation
2017.03.29( 52KB): Announcement regarding the Recording of Extraordinary Loss (Impairment Loss) of the U.S. Subsidiary, Noven Pharmaceuticals, Inc.
2017.03.29(181KB): Announcement regarding Discontinuation (Abolition) of Countermeasures on the Large-scale Purchase of Hisamitsu Shares, etc. (Takeover Defense Measures)
2017.01.13: FY02/2017 Q3 Results Earnings Release Presentation
2016.12.19( 34KB): Notification of application for manufacturing and marketing approval of HP-3060 in Japan (a transdermal system for the treatment of allergic rhinitis)
2016.11.21( 33KB): Notification of acquisition state and acquisition end of company's own shares.
2016.11.04( 35KB): Notification of regarding acquisition of own shares.(Acquisition of company’s own shares under the regulations of the articles of association in accordance to paragraph 2, article 165 of the corporation law)
2016.10.11: FY02/2017 Q2 Results Earnings Release Presentation
2016.09.05( 30KB): Notification of the commencement of the Phase III clinical study of HP-3070 in the United States (a transdermal drug for the treatment of Schizophrenia)
2016.08.29( 34KB): Notification of the results of the Phase II / III clinical study of HP-3150 in Japan for "cancer pain" (an analgesic transdermal drug containing NSAIDs)
2016.07.26( 30KB): Notification of the Noven Pharmaceuticals, Inc. assigns rights for Brisdelle® (Paroxetine) Capsules and Pexeva® (Paroxetine Mesylate) Tablets
2016.07.25( 14KB): Notice Concerning Finalization of Details of Issuance of Stock Options as Compensation
2016.07.25( 34KB): Notification of the results of Phase III clinical study on HP-3060 in Japan (a transdermal system for the treatment of allergic rhinitis)
2016.07.25( 31KB): Notification of the results of Phase II clinical study of HP-3150 in Japan for "Lower back pain" (an analgesic transdermal drug containing NSAIDs)
2016.07.08: FY02/2017 Q1 Results Earnings Release Presentation
2016.07.08( 68KB): Notice Concerning Issuance of Stock Options as Compensation
2016.07.08( 36KB): Announcement Regarding Disposition of Treasury Share through Third-Party Allotment
2016.04.08: FY02/2016 Q4 Results Earnings Release Presentation
2016.04.08(122KB): Announcement Regarding Disposition and Acquisition of Treasury Share through Third-Party Allotment
2016.04.08( 36KB): Announcement of Dividend of Surplus in the Fiscal Year Ended February 2016 (114th Fiscal Year)
2016.01.08: FY02/2016 Q3 Results Earnings Release Presentation
2015.12.11( 37KB): Notification of listing on the NHI drug price standard and marketing of MOHRUS® PAP XR 120mg, a topical analgesic and anti-inflammatory product
2015.12.09( 30KB): Notification of the commencement of the Phase III clinical study of HP-3060 in Japan (a transdermal drug for the treatment of allergic rhinitis)
2015.10.09: FY02/2016 Q2 Results Earnings Release Presentation
2015.09.30( 77KB): Notice of Revision of Financial Forecast
2015.09.30( 38KB): Noven Pharmaceuticals, Inc. press release :Noven announces favorable decisions in the inter partes reviews challenging Novartis' Exelon® Patch patents
2015.09.09( 28KB): Notification of acquisition result and acquisition end of company's own shares.
2015.08.28(152KB): Notification o f the commencement of the Phase II clinical study of HP-3150 Japan for 'Lower back pain'(an analgesic transdermal drug containing NSAIDs )
2015.08.25(146KB): Notice concerning the decision of matters relating to acquisition company's own shares.
2015.08.17(127KB): Notification of the Marketing Approval of MOHRUS®PAP XR a topical analgesic and anti-inflammatory product
2015.07.27( 11KB): Notice Concerning Finalization of Details of Issuance of Stock Options as Compensation
2015.07.10: FY02/2016 Q1 Results Earnings Release Presentation
2015.07.10( 96KB): Notification o f the commencement of the Phase II / III clinical study of HP-3150 Japan (an analgesic transdermal drug containing NSAIDs )
2015.07.10(179KB): Notice Concerning Issuance of Stock Options as Compensation
2015.04.14(189KB): Notification on the commencement of a Phase III clinical study of HP-3000 in Japan (a transdermal drug for the treatment of Parkinson's disease)
2015.04.08( 31KB): Announcement of Dividend Surplus in the Fiscal Year Ended February 2015 (113th Fiscal Year)
2015.04.08( 35KB): Notice Concerning Partial Amendment of the Articles Incorporation
2015.04.08(111KB): Notice Concerning Abolition of Directors' Retirement Benefit System and Granting of Stock Options as Compensation
2015.04.08: FY02/2015 Q4 Results Earnings Release Presentation
2015.03.23( 21KB): Noven Pharmaceuticals, Inc. press release :Noven files patent infringement lawsuit against Actavis
2015.01.09: FY02/2015 Q3 Results Earnings Release Presentation
2014.10.23(15KB): Notification of the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome)
2014.10.20(29KB): Noven Pharmaceuticals, Inc. press release :Noven files patent infringement lawsuit against Actavis
2014.10.09: FY02/2015 Q2 Results Earnings Release Presentation
2014.10.02(21KB): Notice of Revision of Financial Forecast
2014.09.26(220KB): Noven Pharmaceuticals, Inc. press release :Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle® (Estradiol Transdermal System)
2014.08.05(19KB): Notice of Dissolution of US Equity Method Affiliate Vivelle Ventures LLC (d/b/a Novogyne Pharmaceuticals)
2014.07.10: FY02/2015 Q1 Results Earnings Release Presentation
2014.07.02(12KB): Notification of the Noven Pharmaceuticals, Inc. assigns rights for Lithobid® (lithium carbonate tablets)
2014.06.20(12KB): Notification of approval of the additional indication for chronic pain of the transdermal long-acting pain relief patch FENTOS® TAPE (development code: HFT-290)
2014.05.29(26KB): Announcement of 2014 National Commendation for Invention "The Prize of the Commissioner of Japan PatentOffice" - For Invention of anti-inflammatory analgesic patch superior in percutaneous absorbability -
2014.05.13(275KB): 5th Medium-term Management Plan for FY2014-2018
2014.05.13(38KB): Notice Concerning the Establishment of the 5th Medium-term Management Plan
2014.05.07(13KB): Press Release related to the results of Phase II clinical study on HP-3060 in Japan (a transdermal system for the treatment of allergic rhinitis)
2014.04.24(14KB): Notification on the commencement of Phase I clinical trial of HP-3070 in the United States (a transdermal tape formulation for the treatment of schizophrenia)
2014.04.17(36KB): Noven Pharmaceuticals, Inc. press release :Noven announces settlement of LIDODERM® patent litigation
2014.04.10: FY02/2014 Q4 Results Earnings Release Presentation
2014.04.10(16KB): Announcement of Dividend of Surplus in the Fiscal Year Ended February 2014 (112th Fiscal Year)
2014.02.21(33KB): Notification of approval of additional 'indication' and 'dosage and administration' of the estradiol transdermal patch Estrana® Tape 0.72 mg
2014.02.05(13KB): Notification of the results of Phase II clinical study of HP-3000 in Japan (a transdermal drug for the treatment of Parkinson's disease)
2014.01.14(99KB): Noven Pharmaceuticals, Inc. press release :Noven Enters Co-Promotion Agreement with Shionogi for Brisdelle™ (Paroxetine) Capsules
2014.01.09: FY02/2014 Q3 Results Earnings Release Presentation
2013.12.11(29KB): Launch of Abstral® sublingual tablets for Cancer Pain Treatment in Japan
2013.11.05(104KB): Noven Pharmaceuticals, Inc. press release :First and Only FDA-approved, Non-Hormonal Treatment for Moderate to Severe Hot Flashes Now Available by Prescription in U.S. Pharmacies
2013.10.09: FY02/2014 Q2 Results Earnings Release Presentation
2013.10.01(24KB): Notice of Revision of Financial Forecast
2013.09.20(28KB): Announcement regarding the Marketing Approval of Abstral® sublingual tablets for Cancer Pain Treatment
2013.09.19(235KB): Noven Pharmaceuticals, Inc. press release :Menopause Publishes Pivotal Trial Results for Brisdelle™ (Paroxetine) Capsules, an FDA-Approved Non-Hormonal Therapy for Vasomotor Symptoms Associated with Menopause
2013.09.11(14KB): Notification on the commencement of Phase II clinical study of HP-3000 in Japan (a transdermal drug for the treatment of idiopathic restless legs syndrome)
2013.08.30(22KB): Notification about the application for a partial change (Public knowledge-based application) to the approval items of the estradiol transdermal patch Estrana® Tape 0.72 mg
2013.07.31(12KB): Notification of submission of supplemental new drug application (NDA) for the addition of indication for chronic pain on the transdermal, long-acting cancer pain relief patch FENTOS® TAPE (development code: HFT-290)
2013.07.23(150KB): Noven Pharmaceuticals, Inc. press release :Noven announces positive Phase 2 results of investigational d-Amphetamine Transdermal System for ADHD
2013.07.10(15KB): Press Release related to the initiation of Phase 2 clinical study on HP-3060 (a transdermal long-acting system for the treatment of allergic rhinitis)
2013.07.10: FY02/2014 Q1 Results Earnings Release Presentation
2013.07.01(92KB): Noven Pharmaceuticals, Inc. press release :Noven Receives FDA Approval for Brisdelle™ (Paroxetine) Capsules, the First Nonhormonal Therapy for Vasomotor Symptoms Associated with Menopause
2013.05.24(20KB): Announcement of listing on the NHI drug price standard and marketing of NEOXY® Tape 73.5 mg, transdermal overactive bladder treatment medication
2013.05.14(12KB): Notification of the results of the Phase II clinical study in the United States of HTU-520 (terbinafine hydrochloride patch), a therapeutic agent for tinea unguium.
2013.04.11: FY02/2013 Q4 Results Earnings Release Presentation
2013.04.11( 20KB): Announcement of Change in Executives
2013.04.04( 40KB): Noven Pharmaceuticals, Inc. press release :Noven confirms filing of Abbreviated New Drug Application for generic version of Exelon® (rivastigmine transdermal system)
2013.03.28( 13KB): Notice Regarding Change in the Board of Directors
2013.03.28( 8KB): Board Personnel
2013.03.25( 34KB): Notification of the approval of a production and sales permit for NEOXY®Tape 73.5mg, overactive bladder treatment medication (oxybutynin hydrochloride, transdermal therapeutic formulation, development code: HOB-294)
2013.03.08( 11KB): Notification on the results of the phase III clinical study in Japan for the addition of efficacy for “chronic pain” using the transdermal, long-acting cancer pain relief patch FENTOS® TAPE (development code: HFT-290)
2013.03.06(232KB): Noven Pharmaceuticals, Inc. press release :Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
2013.01.10: FY02/2013 Q3 Results Earnings Release Presentation
2013.01.7( 37KB): Notice Pertaining to the Joint Distribution of Transdermal Pain Reliever and Anti-Inflammatory Mohrus®Pap 30mg and Mohrus®Pap 60mg
2012.12.04(198KB): Noven Pharmaceuticals, Inc. press release : Noven acquires commercial rights to Minivelle™ (estradiol transdermal system)
2012.11.13( 20KB): Notice of Filing of New Drug Application for Approval to Manufacture and Sell Cancer Pain Drug KW-2246
2012.11.13( 37KB): Noven Pharmaceuticals, Inc. press release : FDA accepts Noven's NDA for an investigational nonhormonal therapy for menopausal vasomotor symptoms
2012.10.10: FY02/2013 Q2 Results Earnings Release Presentation
2012.10.04( 53KB): Noven Pharmaceuticals, Inc. press release : Noven annouces positive Phase 3 data results for investigational low-dose nonhormonal therapy for the treatment of vasomotor symptoms associated with menopause
2012.10.03(199KB): Noven Pharmaceuticals, Inc. press release : Noven annouces commencement of Phase 2 study of investigational d-Amphetamine Transdermal System for ADHD
2012.09.26( 25KB): Notice of Revision Financial Forecast
2012.08.30( 29KB): Noven Pharmaceuticals, Inc. press release : Noven submits New Drug Application for investigational non-hormonal therapy for menopausal vasomotor symptoms
2012.08.02( 23KB): Notification regarding Acquisition of Kurumin Mark Certification Based on the Law for Measures to Support the Development of the Next Generation
2012.07.10: FY02/2013 Q1 Results Earnings Release Presentation
2012.07.02( 31KB): Noven Pharmaceuticals, Inc. press release : Noven provides update on Lidoderm® patent challenge (Paragraph IV Litigation Initiated by Patent Holders)
2012.07.02( 13KB): Notice of Personnel Changes
2012.07.02( 20KB): Announcement of marketing of “Fentanyl 3-day tape ‘HMT’”, a dermally absorbed remedy for persistent cancer pain
2012.06.21(12KB): The dispatch of directors to Yutoku Pharmaceutical Ind. Co., Ltd.
2012.06.18(12KB): Notice of dissolution and liquidation of subsidiaries (dormant companies)
2012.06.12(32KB): Establishment of Joint Venture for OTC Allergy Medications
2012.05.24(24KB): Notice of Personnel Changes
2012.05.18(7KB): Application filed for Overactive Bladder Drug HOB-294 (Oxybutynin Hydrochloride, Transdermal Therapeutic Formulation)
2012.04.25(15KB): Results of a Japanese Phase III Clinical Study of HTU-520 (Terbinafine Hydrochloride Patch): A Therapeutic Agent for Tinea Unguium
2012.04.10: FY02/2012 Q4 Results Earnings Release Presentation
2012.04.03(12KB): Announcement on Launching the Topical Analgesic Patch “SALONPAS” in Chinese market
2012.03.28(36KB): Notice of Appointment of Executive Officer
2012.03.21(40KB): Noven Pharmaceuticals, Inc. press release : Noven completes Phase3 clinical program for investigational non-hormonal therapy for menopausal vasomotor symptoms
2012.01.17(83KB): Regarding the Capital and Business Partnership with Yutoku Pharmaceutical lnd. Co., Ltd.
2012.01.12: FY02/2012 Q3 Results Earnings Release Presentation
2011.12.26(35KB): Noven Pharmaceuticals, Inc. press release : Noven announces Phase3 results for investigational non-hormonal therapy for vasomotor symptoms
2011.10.27(32KB): Announcement on the Establishment of a Local Corporation in China
2011.10.17(28KB): Noven Pharmaceuticals, Inc. press release : Noven files patent infrigement lawsuit against Watson Pharmaceuticals
2011.10.12: FY02/2012 Q2 Results Earnings Release Presentation
2011.09.21(12KB): Notification of Termination of Agreement Concerning Co-promotion of Fosamac®
2011.08.11(12KB): Phase III Clinical Trial Results for Overactive Bladder Drug HOB-294
(Oxybutynin Hydrochloride, Transdermal Therapeutic Formulation)
2011.07.21(41KB): Notice of the availability of Norspan® Tape, a dermally absorbed remedy for persistent pain.
2011.07.07(83KB): Announcement on Estimated Business Results and Dividends
2011.07.07: FY02/2012 Q1 Results Earnings Release Presentation
2011.05.26(32KB): Notice of Personnel Changes
2011.04.15(12KB): Announcement Regarding the Impact of the Great Eastern Earthquake (3rd)
2011.04.08: FY02/2011 Q4 Results Earnings Release Presentation
2011.03.25(37KB): Notice of Appointment of Executive Officer
2011.03.25(38KB): Notice of Proposed Changes of Directors and Auditors
2011.03.23(12KB): Announcement Regarding the Impact of the Tohoku-Pacific Ocean Earthquake (2nd)
2011.03.15(17KB): Notice concerning the decision of matters relating to acquisition of company’s own shares.
(Acquisition of company’s own shares under the regulations of the articles of association in accordance to paragraph 2, article 165 of the corporation law)
2011.03.15(13KB): Announcement Regarding the Impact of the Tohoku-Pacific Ocean Earthquake
2011.03.15(9KB): Announcement Regarding Relief Money for the Tohoku-Pacific Ocean Earthquake
2011.02.23(23KB): Announcement of the acquisition of marketing approval for transdermal long-acting chronic pain "NORSPAN® TAPE" (development code: BTDS)
2011.02.23(24KB): Transdermal Pain Reliever and Anti-Inflammatory "Mohrus Tape®" (Development Code: KPT-220)
Notice Pertaining the Acquisition of Approval to Add the Effects Related to "Pain and Inflammation Relief for Acute Disorders and Symptoms"
2011.02.22(52KB): Noven Pharmaceuticals, Inc. press release : Noven files patent infrigement lawsuit against Mylan Technologies
2011.01.06: FY02/2011 Q3 Results Earnings Release Presentation
2010.10.05: FY02/2011 Q2 Results Earnings Release Presentation
2010.10.01(72KB): Noven Pharmaceuticals, Inc. press release : Noven completes acquisition of Daytrana® methylphenidate transdermal system (CII) from Shire
2010.08.27(13KB): Conduct ofAdditional Clinical Study of KW-2246, a Cancer Pain Drug
2010.08.11(77KB): Noven Pharmaceuticals, Inc. press release : Noven to acquire Daytrana® methylphenidate transdermal system from Shire
2010.06.30: FY02/2011 Q1 Results Earnings Release Presentation
2010.06.14(26KB): Financial Support to SAGA Heavy Ion Medical Accelerator in Tosu Project
2010.06.11(16KB): Announcement of Listing of "FENTOS® TAPE," a transdermal, long-acting cancer pain relief patch, on the NHI Drug Price Standard
2010.05.26(11KB): Notice of Application for Delisting of Stock on Osaka Stock Exchange
2010.05.26(51KB): Notice of Personnel Changes
2010.04.23(11KB): Results of Phase III Clinical Trial of HKT-500 in the USA
2010.04.16(13KB): Hisamitsu Pharmaceutical Announces Marketing Approval of FENTOS® TAPE (Development Code: HFT-290), Transdermal, Long-Acting Cancer Pain Relief Patch
2010.04.08: FY02/2010 Q4 Results Earnings Release Presentation
2010.03.25(19KB): Hisamitsu Announces U.S. Launch of its "Fentanyl Transdermal System" for the Management of Chronic Pain
2010.03.24(42KB): Revision of Earnings Forecast
2010.02.25(15KB): Application Filed for Cancer Pain Drug (KW-2246)
2010.02.01(13KB): Kyowa Hakko Kirin and Hisamitsu entered into a Joint Distribution Agreement on Cancer Pain Drug (Development Code: KW-2246)
2010.01.08: FY02/2010 Q3 Results Earnings Release Presentation
2009.12.11(76KB): Notice concerning acquisition result and acquisition end of company?fs own shares. (Acquisition of company?fs own shares under the regulations of the articles of association in accordance to paragraph 2, article 165 of the corporation law)
2009.12.03(62KB): Investment in Kind to our Subsidiary in the US
2009.11.12(17KB): Notice concerning the decision of matters relating to acquisition of company's own shares. (Acquisition of company's own shares under the regulations of the articles of association in accordance to paragraph 2, article 165 of the corporation law)
2009.11.09(22KB): Additional Indication (For relief of local pain associated with rheumatoid arthritis) Approved for "MOHRUS Tape," a topical analgesic and anti-inflammatory product (Development Code: KPT-220)
2009.10.19(97KB): Hisamitsu Announces FDA Approval of its Fentanyl Transdermal System for Management of Chronic Pain (Development code: HFG-512)
2009.09.30: FY02/2010 Q2 Results Earnings Release Presentation
2009.08.28(43KB): Completion of the tender offer for acquisition of shares of Noven Pharmaceuticals, Inc. by our subsidiary
2009.08.25(42KB): Results of a Phase II clinical study of HTU-520 (terbinafine hydrochloride, patch), atherapeutic agent for tinea unguium
2009.08.21(94KB): Results of tender offer for acquisition of Noven Pharmaceuticals, Inc. by our subsidiary
2009.08.06(30KB): Phase II study results of HOB-294 (transdermal oxybutynin hydrochloride) for treatment of overactive bladder
2009.07.27(308KB): The 4th Medium Term Management Plan
2009.07.27(25KB): 4th Medium-term Management Objectives
2009.07.14(129KB): Acquisition of Noven Pharmaceuticals,Inc.
2009.07.14(74KB): Hisamitsu to Acquire US-based Noven Pharmaceuticals Inc.
2009.06.30: FY02/2010 Q1 Results Earnings Release Presentation
2009.04.07: FY02/2009 Q4 Results Earnings Release Presentation
2009.03.24(67KB): Modification of Earnings Forecast
2009.03.18(30KB): Notice concerning acquisition result and acquisition end of company's own shares.
2009.02.26(37KB): Notice concerning the decision of matters relating to acquisition of company's own shares.
2009.01.23(23KB): Co-Promotion Agreement of "FOSAMAC"
2008.12.25: FY02/2009 Q3 Results Earnings Release Presentation
2008.10.31(12KB): Application filed for a transdermal patch containing buprenorphine designed to control moderate to severe, chronic lower back and osteoarthritis pain (Development code: BTDS)
2008.10.09: FY02/2009 Q2 Results Earnings Pelease Presentation
2008.09.25(93KB): Notice Regarding Performance Forecasts
2008.07.01: FY02/2009 Q1 Results Earnings Pelease Presentation
2008.06.26(31KB): Application filed for a transdermal absorption-type continuous-action drugto treat cancer pain(Development code: HFT-290)
2008.06.18(31KB): Conclusion of a joint sales agreement on a transdermal absorption-type continuous-action drug to treat cancer pain(Development code: HFT-290)
2008.04.08: FY02/2008 Q4 Results Earnings Pelease Presentation
2008.03.27(150KB): Information on Countermeasures(Takeover Defenses) for Large-scale Purchases of Hisamitsu Stock
2008.02.22(18KB): Press Release relating to FDA Approval for SALONPASR PAIN RELEAF PATCH (code: FS-67, topical analgesic product) under NDA
2007.12.27: FY02/2008 Q3 Results Earnings Pelease Presentation
2007.08.06(40KB): Press Release relating to the Exclusive Sales and Distribution Rights for NORSPAN
2006.09.26: SALONPAS CUP 2006 - International women's volleyball tournaments in Sao Paulo, Brazil
topics
table of games and results
more details
2005.11.01(196KB): FINANCIAL REPORT Fiscal 2005
2005.08.24: SALONPAS CUP 2005 - International women's volleyball tournaments August 26 to September 3 in Sao Paulo, Brazil
topics
table of games and results
more details
2004.10.04: SALONPAS CUP 2004 International women?fs volleyball tournaments October 2 to 10 in Sao Paulo,Brazil
organization
table of games and results
more details
topics
2003.07.01: PT.Salonpas Indonesia has changed its company name to PT.Hisamitsu Pharma Indonesia
2003.05.26: "SALONPAS CUP" (International Tournament of Women's Volley Ball in Brazil) home page renovated
2003.03.10: Our Home Page Completely Renovated
2002.10.04: Announcing the interim-closing brief report for the FY 2002 (ended February 2003)
2002.10.04: Announcement of the Sales Contract Agreement of "KETOPATCH", the External Pain Relieving Drug for Medical Application with SIGMA-TAU (Italy)